Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : SangStat Med. (SANG) - 10 of 10 analysts say Strong Buy -- Ignore unavailable to you. Want to Upgrade?

To: Richard Haugland who wrote (114)	6/9/1998 3:07:00 PM
From: Doug	Read Replies (2) \| Respond to of 184

Richard: I have a few Q's pertaining to SANG. Since you have been a regular contributor, I would much appreciate your input. a: What is the current unit cost of preserving and preventing organ rejection.? b: Are SANG's replacement products high margin.? c: What is the size of the market in the U.S and globally. How is this market being served currently .? d: Are there likely to be liabilty suits from patients facing transplant rejection.? e: Will patients with these transplants have to be specially monitored for life. If negative , has the Company any long term liabilty.? Thx.